American International Group, Inc. Hille Vax, Inc. Transaction History

American International Group, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$14.15 - $19.75 $1,556 - $2,172	-110 Reduced 0.84%	12,921 $214,000
Q4 2023 Feb 13, 2024	BUY	$10.35 - $17.11 $25,222 - $41,697	2,437 Added 23.0%	13,031 $209,000
Q3 2023 Nov 13, 2023	BUY	$11.59 - $16.7 $4,381 - $6,312	378 Added 3.7%	10,594 $142,000
Q2 2023 Aug 04, 2023	BUY	$12.93 - $18.76 $23,157 - $33,599	1,791 Added 21.26%	10,216 $175,000
Q1 2023 May 12, 2023	BUY	$14.73 - $18.18 $2,459 - $3,036	167 Added 2.02%	8,425 $139,000
Q4 2022 Feb 10, 2023	BUY	$13.52 - $21.46 $28,459 - $45,173	2,105 Added 34.21%	8,258 $138,000
Q3 2022 Nov 14, 2022	BUY	$10.5 - $22.01 $913 - $1,914	87 Added 1.43%	6,153 $105,000
Q2 2022 Aug 12, 2022	BUY	$8.7 - $20.18 $52,774 - $122,411	6,066 New	6,066 $66,000

36.8M

Ticker HLVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,427,200
Market Cap $65.5M
Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.